Company intelligence / Profile preview
Nanjing Kati Medical Technology
Nanjing, Jiangsu, Chinacart-med.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Nanjing Kati Medical Technology is a clinical-stage company with multiple CAR-T cell therapy programs for malignant solid tumors, focusing on overcoming tumor microenvironment resistance and anti-exhaustion mechanisms. Clinical trials have begun for at least one CD19 CAR-T program; clinical partnership work is ongoing for expanding targets and solid-tumor application.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyTCR-T cell therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Leman BiotechShenghe Pharmaceutical
Beyond the preview
Go deeper on Nanjing Kati Medical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanjing Kati Medical Technology.